INS and Alzheimer disease: In recent months, the first multicenter, randomized, double-blind (phase 2/3) clinical trial evaluating the feasibility, safety and efficacy of intranasal insulin in the treatment of patients (ages 55 to 85) with mild cognitive impairment and dementia in AD was released.